AK105 (Anti-PD-1 Antibody)

anti-PD-1 antibody · Peking Union Medical College Hospital (sponsor)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AK105 (Anti-PD-1 Antibody), covering 2023-06-22 to 2023-06-22. Get the full timeline:

Most recent: Clinical Trial Update: Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer [Phase 1, Phase 2]